Ana Ciornei

Ana Ciornei

Auto-generated profile, based on publicly available information

Ana Ciornei

Department of Radiotherapy II, “Prof. Dr. Al. Trestioreanu” Institute of Oncology, 022328 Bucharest, Romania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OTOana Gabriela Trifanescu
Oana Gabriela Trifanescu
DMDan Andrei Mitrea
Dan Andrei Mitrea
LGLaurentia Nicoleta Gales
Laurentia Nicoleta Gales
ACAna Ciornei
Ana Ciornei
MPMihai-Andrei Păun
Mihai-Andrei Păun
RARodica Maricela Anghel
Rodica Maricela Anghel
Leptomeningeal metastases (LM) are a rare but rapidly fatal complication defined by the spread of tumor cells within the leptomeninges and the subarachnoid space, found in approximately 10% of patients with HER2-positive breast cancers. This pilot study evaluated the efficacy of local treatment with intrathecal Trastuzumab (IT) added to systemic treatment. The oncologic outcome of 14 patients with HER2-positive LM is reported. Seven received IT, and seven received standard of care (SOC). The mean number of IT cycles administered was 12.14 ± 4.00. The response rate to CNS after IT treatment + SOC was 71.4%, and three patients (42.8%) obtained durable responses lasting more than 12 months. The median progression-free survival (mPFS) after LM diagnosis was six months, and the median overall survival (mOS) was ten months. The mean values of the PFS in favor of IT therapy (10.6 mo vs. 6.6 mo) and OS (13.7 vs. 9.3 mo) suggest a non-negligible investigation direction in the sense of exploiting intrathecal administration as a possible treatment modality in these patients. Adverse events reported were local pain related to intrathecal administration and one case of arachnoiditis, hematoma, and CSF fistulae. Intrathecal administration of Trastuzumab, alongside systemic treatment and radiotherapy, might improve oncologic outcomes in LM HER2-positive breast cancer with manageable toxicity.

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
OTOana Gabriela Trifanescu
Oana Gabriela Trifanescu
LGLaurentia Nicoleta Gales
Laurentia Nicoleta Gales
ACAna Ciornei
Ana Ciornei
Dan MitreaDan Mitrea
Dan Mitrea
RARodica Maricela Anghel
Rodica Maricela Anghel
E13021 Background: Leptomeningeal metastases are rare but fatal manifestation of metastatic breast cancer, especially in HER2 positive sub-type, with limited treatment options and median overall survival in the range of only 4-6 weeks in untreated patients. Methods: Our prospective study included 9 patients with HER2 positive breast cancer with leptomeningeal metastases that received intrathecal treatment with Trastuzumab along with systemic therapy. Data was compared with a control lot of 9 patients with leptomeningeal metastasis that did not receive intrathecal treatment. Radiotherapy was administered in all patients. The patients included in the study received cures of 150 mg of Trastuzumab injected intrathecal every 3 weeks. Results: Median age of the patients at the time of diagnosis was 53 years. Median time from diagnosis of BC until diagnosis of leptomeningeal carcinomatosis was 3.4 years. Median progression free survival for patients receiving trastuzumab intrathecal was 11.1 months compare with 6.4 months in patients receiving standard treatment, p < 0.019. In our lot of patients, response rate was 66.6%. A clinical benefit with symptoms relief was observed in 77.7% of patients. Mean number of administrations was 12. Two patients presented pain and in two instance the administration was not possible. Concurrent systemic treatment consisted in lapatinib and capecitabine (22.2%), trastuzumab emtansine (44.5%), tucatinib combination (22.2%), vinorelbine (11.1%) and no unexpected toxicity to systemic treatment was noticed. Conclusions: Intrathecal administration of trastuzumab along with systemic treatment and radiotherapy, might improve or stabilise the consequences of leptomeningeal involvement by HER2-positive breast cancer with manageable toxicity.